The Use of Anticonvulsant Adjuncts to Treat Alcohol Withdrawal Syndrome in Older Adults.

Autor:	Montgomery S; Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC., Dahri K; Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC.; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC., Rayani K; Faculty of Medicine, University of British Columbia, Vancouver, BC., Kwok J; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC., Chan P; Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, BC.; Geriatrics, Vancouver General Hospital, Vancouver, BC.
Jazyk:	angličtina
Zdroj:	Canadian geriatrics journal : CGJ [Can Geriatr J] 2022 Mar 02; Vol. 25 (1), pp. 32-39. Date of Electronic Publication: 2022 Mar 02 (Print Publication: 2022).
DOI:	10.5770/cgj.25.544
Abstrakt:	Background: We evaluated the prescribing practices of anticonvulsant (AC) adjuncts to benzodiazepines in managing Alcohol Withdrawal Syndrome (AWS). We also examined the prescription of relapse prevention agents for Alcohol Use Disorder (AUD), and adverse events related to AWS treatment. Methods: Records were reviewed retrospectively pertaining to medically ill adults aged 60 and above with AWS and admitted to a medicine or hospitalist unit of a Canadian centre between June 2013 and June 2018. Duration and dosing of benzodiazepine, dosing and type of AC and AUD agent, and adverse events were collected. A multivariable regression model was employed. Results: 83 encounters were included in the study and 28 were prescribed an AC. The amount and duration of benzodiazepine administered were not statistically different between the benzodiazepine only and the AC adjunct groups, once severe AWS complications were accounted for. Five new prescriptions of traditional AUD agents were provided on discharge. No AC-associated adverse events occurred. Conclusions: AC adjuncts for AWS did not decrease the amount of benzodiazepine administered nor shorten the duration of treatment. Their routine use is not supported by our findings. Our study highlights a missed opportunity for AUD agents to be prescribed during hospitalization. Competing Interests: CONFLICT OF INTEREST DISCLOSURES We have read and understood the Canadian Geriatrics Journal’s policy on conflicts of interest disclosure and declare the following interests: Peter Chan is on the advisory board for Janssen-Ortho. The other authors have no conflicts of interest to declare. (© 2022 Author(s). Published by the Canadian Geriatrics Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu